Brief: Cue Biopharma Presents Positive Data Update From Ongoing Phase 1 Trials Of Cue-101 For Recurrent/Metastatic Hpv+ Head And Neck Squamous Cell Carcinoma At The 2023 American Society Of Clinical Oncology Annual Meeting
25/05/2023 23:10
May 25 (Reuters) - Cue Biopharma Inc CUE.O :
* CUE BIOPHARMA PRESENTS POSITIVE DATA UPDATE FROM ONGOING
PHASE 1
TRIALS OF CUE-101 FOR RECURRENT/METASTATIC HPV+ HEAD AND NECK
SQUAMOUS CELL CARCINOMA AT THE 2023 AMERICAN SOCIETY OF CLINICAL
ONCOLOGY (ASCO) ANNUAL MEETING
* CUE BIOPHARMA - 100% OF PATIENTS TREATED WITH CUE-101+
PEMBROLIZUMAB AT RECOMMENDED PHASE 2 DOSE REMAIN ALIVE TO DATE
FOLLOWING TREATMENT IN STUDY
Source text for Eikon: ID:nGNX1g1CMx
Further company coverage: CUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cue Biopharma
See all newsU.S. STOCKS ON THE MOVE-Insmed, Marvell, Meta
US STOCKS ON THE MOVE-Meta, Marvell Technology, Insmed
U.S. STOCKS ON THE MOVE-Accenture, Arhaus, Alkermes
Cue Biopharma surges after positive results from mid-stage study for CUE-221
Brief: Cue Biopharma Announces Positive Topline Results From Cue-221 Phase 2 Study In Chronic Spontaneous Urticaria